MARKET

MNKD

MNKD

Mannkind
NASDAQ
4.930
+0.020
+0.41%
Opening 11:23 04/30 EDT
OPEN
4.910
PREV CLOSE
4.910
HIGH
5.02
LOW
4.880
VOLUME
595.52K
TURNOVER
--
52 WEEK HIGH
7.63
52 WEEK LOW
4.110
MARKET CAP
1.50B
P/E (TTM)
50.72
1D
5D
1M
3M
1Y
5Y
1D
Strong Revenue Growth and Market Expansion Drive Buy Rating for MannKind
TipRanks · 59m ago
Weekly Report: what happened at MNKD last week (0421-0425)?
Weekly Report · 2d ago
Weekly Report: what happened at MNKD last week (0414-0418)?
Weekly Report · 04/21 10:36
MannKind Becomes Oversold (MNKD)
NASDAQ · 04/16 21:09
Weekly Report: what happened at MNKD last week (0407-0411)?
Weekly Report · 04/14 10:30
This Ligand Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday
Benzinga · 04/10 13:00
MANNKIND CORP <MNKD.O>: MIZUHO INITIATES COVERAGE WITH OUTPERFORM RATING; PRICE TARGET $12
Reuters · 04/10 11:30
MannKind Initiated at Outperform by Mizuho
Dow Jones · 04/10 11:26
More
About MNKD
More
MannKind Corporation is focused on the development and commercialization of inhaled therapeutic products and devices to address serious unmet medical needs for those living with endocrine and orphan lung diseases. The Company's technologies include Technosphere dry-powder formulations and Dreamboat inhalation devices. In its endocrine business unit, it commercializes two products: Afrezza (insulin human) Inhalation Powder, an ultra rapid-acting inhaled insulin indicated to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults that require insulin. Its orphan lung disease product, Tyvaso DPI (treprostinil) inhalation powder, is used in the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). Its pipeline products include Pediatric Afrezza (insulin human) Inhalation Powder, MNKD-101 and MNKD-201.
Recently
Symbol
Price
%Change

Webull offers MannKind Corp stock information, including NASDAQ: MNKD real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, MNKD stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading MNKD stock methods without spending real money on the virtual paper trading platform.